InsidersTradesSigma
Explore the full directors' dealings record of Dermira, Inc., a publicly traded company based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was reported on 3 February 2016 (Cession). Among the most active insiders: BAUER EUGENE A. The full history is accessible without an account.
Analysts rate Dermira, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
8 of 8 declarations
Dermira, Inc. is a biopharmaceutical company focused on developing treatments for skin diseases. It is listed on the XNAS market.